Literature DB >> 10082245

In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment.

J Tauscher1, W Pirker, M de Zwaan, S Asenbaum, T Brücke, S Kasper.   

Abstract

Beta-CIT can be used as a tracer for SPECT to visualize serotonin transporters in the human brain. We present a case of bulimia nervosa and major depressive disorder, who had been treated with up to 60 mg/d fluoxetine for several weeks. Four hours after injection of the tracer more than 40% of serotonin transporters were blocked. To our knowledge, this is the first direct documentation of the pharmacodynamic action of fluoxetine in the human brain in vivo.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10082245     DOI： 10.1016/s0924-977x(98)00013-3

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN： 0924-977X            Impact factor:   4.600


  8 in total

1.  Treatment improves serotonin transporter binding and reduces binge eating.

Authors:  Liisa I Tammela; Aila Rissanen; Jyrki T Kuikka; Leila J Karhunen; Kim A Bergström; Eila Repo-Tiihonen; Hannu Naukkarinen; Esko Vanninen; Jari Tiihonen; Matti Uusitupa
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

2.  The Effect of SSRIs on the Binding of (18)F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study.

Authors:  Minjung Seo; Minyoung Oh; Minjung Cho; Sun Ju Chung; Chong Sik Lee; Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2014-07-03

3.  Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.

Authors:  Ana M Catafau; Victor Perez; Pedro Plaza; Juan-Carlos Pascual; Santiago Bullich; Marina Suarez; Maria M Penengo; Iluminada Corripio; Dolors Puigdemont; Monica Danus; Javier Perich; Enric Alvarez
Journal:  Psychopharmacology (Berl)       Date:  2006-10-11       Impact factor: 4.530

Review 4.  Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.

Authors:  S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.

Authors:  N Klein; J Sacher; T Geiss-Granadia; T Attarbaschi; N Mossaheb; R Lanzenberger; C Pötzi; A Holik; C Spindelegger; S Asenbaum; R Dudczak; J Tauscher; S Kasper
Journal:  Psychopharmacology (Berl)       Date:  2006-09-06       Impact factor: 4.530

Review 6.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.

Authors:  Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

7.  Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM.

Authors:  N Herold; K Uebelhack; L Franke; H Amthauer; L Luedemann; H Bruhn; R Felix; R Uebelhack; M Plotkin
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.850

8.  Recent progress of imaging agents for Parkinson's disease.

Authors:  Xiaoai Wu; Huawei Cai; Ran Ge; Lin Li; Zhiyun Jia
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.